Famim Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Famim Ahmed has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Akram Hossain
Daffodil International University, Bangladesh
1 shared publicationApurba Kumar Barman
Affiliation Department of Pharmacy, R. P. Shaha University, Naryanganj, Bangladesh
1 shared publicationArju Hossain
Affiliation Department of Biochemistry and Biotechnology, Khwaja Yunus Ali University, Sirajganj, Bangladesh
1 shared publication- Farjana Khatun
Khwaja Yunus Ali University, Bangladesh
1 shared publication - Imran Mahmud
Affiliations Department of Life Technologies, Biotechnology Division, University of Turku, Turku, Finland, Department of Pharmacy, Khwaja Yunus Ali University, Sirajganj, Bangladesh
1 shared publication Jakaria Islam
Affiliation Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh
1 shared publication
Latest Publications
- 20 February 2026
- Published by Elsevier in Veterinary Parasitology
- Vol. 343, 110725
Chemico-pharmacological and computational evaluation of Artocarpus chaplasha; Comparative anthelmintic and cytotoxic potential between bark and seed
- 20 February 2026
- Published by Elsevier in Veterinary Parasitology
- Vol. 343, 110725
Chemico-pharmacological and computational evaluation of Artocarpus chaplasha; Comparative anthelmintic and cytotoxic potential between bark and seed
- Open Access
- 5 November 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (11) , e0335403
GCMS profiling of bioactive phytocompounds from Curculigo orchiodes Gaertn. root extract and evaluation of antioxidant, and antidiabetic activities: A computational drug development approach
Curculigo orchioides (C. orchioides), a traditionally valued medicinal plant, has been utilized for centuries in the management of various ailments, but its full spectrum of therapeutical potentials remains underexplored. This study aimed to perform GC-MS profiling of bioactive phytochemicals as well as to evaluate the antioxidant and anti-diabetic properties of the ethanolic root extract of C. orchioides (ERCO) through an integrative approach combining in vitro , in vivo , and in silico methods. Phytochemical screening confirmed the presence of some major bioactive phytochemical groups including alkaloids, flavonoids, tannins, saponins, and steroids which are well-known for their pharmacological relevance. Antioxidant activity was demonstrated through high levels of total phenolic content (TPC), total flavonoid content (TFC), total tannin content (TTC) determined as 44.055 mg GAE/gm, 0.6768 mg QE/gm, and 103.375 mg TAE/gm of dry weight extract, respectively, along with notable ferric reducing antioxidant power (FRAP). Anti-diabetic potential was supported by significant in vitro inhibition of pancreatic α -amylase and α -glucosidase enzymes, with IC 50 values of 84.17 μg/mL and 36.33 μg/mL, respectively. In vivo studies in alloxan-induced diabetic mice further validated the extract’s substantial blood glucose-reduction abilities (47.28% and 52.11% at the dose of 100 mg/kg and 200 mg/kg body-weight, respectively), indicating the potential for blood sugar regulation. GC-MS profiling confirmed the presence of 23 major phytochemicals, which were subjected to molecular docking studies against human glutathione peroxidase, peroxiredoxin 5, Catalase, sulfonylurea receptor 1 (SUR1), α-amylase, and α-glucosidase. Among them, 2-epoxy-3,4-dihydroxycyclohexano[a]pyrene (CID: 41322) emerged as a lead compound, exhibiting strong binding affinities for both α-amylase (−9.1 kcal/mol) and α-glucosidase (−8.8 kcal/mol). ADMET predictions and stable molecular dynamics simulation outcomes further underscored its drug-likeness. Collectively, these findings position ERCO as a promising source of natural antioxidants and anti-diabetic agents, while identifying 2-epoxy-3,4-dihydroxycyclohexano[a]pyrene as a potential therapeutic lead. This investigation provides a foundation for future drug development, and, further experimental validations, isolation of active compounds, and subsequent clinical studies are required to validate its safety and efficacy.
- 5 November 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (11) , e0335403
Open AccessGCMS profiling of bioactive phytocompounds from Curculigo orchiodes Gaertn. root extract and evaluation of antioxidant, and antidiabetic activities: A computational drug development approach
Curculigo orchioides (C. orchioides), a traditionally valued medicinal plant, has been utilized for centuries in the management of various ailments, but its full spectrum of therapeutical potentials remains underexplored. This study aimed to perform GC-MS profiling of bioactive phytochemicals as well as to evaluate the antioxidant and anti-diabetic properties of the ethanolic root extract of C. orchioides (ERCO) through an integrative approach combining in vitro , in vivo , and in silico methods. Phytochemical screening confirmed the presence of some major bioactive phytochemical groups including alkaloids, flavonoids, tannins, saponins, and steroids which are well-known for their pharmacological relevance. Antioxidant activity was demonstrated through high levels of total phenolic content (TPC), total flavonoid content (TFC), total tannin content (TTC) determined as 44.055 mg GAE/gm, 0.6768 mg QE/gm, and 103.375 mg TAE/gm of dry weight extract, respectively, along with notable ferric reducing antioxidant power (FRAP). Anti-diabetic potential was supported by significant in vitro inhibition of pancreatic α -amylase and α -glucosidase enzymes, with IC 50 values of 84.17 μg/mL and 36.33 μg/mL, respectively. In vivo studies in alloxan-induced diabetic mice further validated the extract’s substantial blood glucose-reduction abilities (47.28% and 52.11% at the dose of 100 mg/kg and 200 mg/kg body-weight, respectively), indicating the potential for blood sugar regulation. GC-MS profiling confirmed the presence of 23 major phytochemicals, which were subjected to molecular docking studies against human glutathione peroxidase, peroxiredoxin 5, Catalase, sulfonylurea receptor 1 (SUR1), α-amylase, and α-glucosidase. Among them, 2-epoxy-3,4-dihydroxycyclohexano[a]pyrene (CID: 41322) emerged as a lead compound, exhibiting strong binding affinities for both α-amylase (−9.1 kcal/mol) and α-glucosidase (−8.8 kcal/mol). ADMET predictions and stable molecular dynamics simulation outcomes further underscored its drug-likeness. Collectively, these findings position ERCO as a promising source of natural antioxidants and anti-diabetic agents, while identifying 2-epoxy-3,4-dihydroxycyclohexano[a]pyrene as a potential therapeutic lead. This investigation provides a foundation for future drug development, and, further experimental validations, isolation of active compounds, and subsequent clinical studies are required to validate its safety and efficacy.